Welcome to our dedicated page for Tarsus Pharmaceuticals SEC filings (Ticker: TARS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to trace how FDA milestones, trial costs, and insider sales shape Tarsus Pharmaceuticals (TARS) prospects? Biotech filings run hundreds of pages, packed with clinical jargon about XDEMVY, TP-04, and TP-05. Missing a single risk factor in the annual report could skew your valuation.
Stock Titan solves that problem by pairing real-time EDGAR feeds with AI-powered summaries. Whether you need the Tarsus Pharmaceuticals quarterly earnings report 10-Q filing or a quick take on an 8-K announcing pivotal trial results, our platform highlights cash runway, trial endpoints, and revenue clues in plain language. Wondering about Tarsus Pharmaceuticals insider trading Form 4 transactions? Get instant alerts the moment executives buy or sell shares.
Here’s what you can uncover in seconds:
- Tarsus Pharmaceuticals annual report 10-K simplified � find R&D spend, patent timelines, and Demodex market sizing.
- Tarsus Pharmaceuticals Form 4 insider transactions real-time � monitor executive stock moves around FDA approvals.
- Tarsus Pharmaceuticals proxy statement executive compensation � see how milestone payouts align with shareholder value.
- Tarsus Pharmaceuticals 8-K material events explained � track trial readouts and licensing deals without wading through legalese.
Investors use these insights to compare quarter-over-quarter burn rates, gauge pipeline momentum, and spot early red flags. Understanding Tarsus Pharmaceuticals SEC documents with AI means faster, better-informed decisions—no medical dictionary required.
First American Financial Corporation (FAF) filed Amendment No. 4 to Schedule 13D on 07/28/2025, reporting its current ownership in Offerpad Solutions Inc. (OPAD).
- FAF beneficially owns 5,119,314 Class A shares, equal to 16.84 % of the 27,710,358 shares outstanding as of 06/30/2025.
- All shares are held with sole voting and dispositive power; there is no shared ownership.
- Shares were acquired using working capital (Item 3); no leverage or third-party financing is referenced.
- Item 5(c) states no reportable transactions since the prior amendment; the filing primarily updates the percentage of ownership.
- FAF confirms it has not faced criminal convictions and, aside from matters disclosed in its March 30 2023 13D/A, is not subject to material legal orders.
The document signals that FAF remains a strategic, non-activist holder of a sizable OPAD position; no change in intent, control, or additional purchases/sales is disclosed.
Form 4 highlights for Tarsus Pharmaceuticals (TARS): CFO & Chief Strategy Officer Jeffrey S. Farrow reported the settlement of 27,881 restricted stock units (RSUs) on 16-Jun-2025, converting them into an equal number of common shares (Code M). The following day, 13,608 shares were sold at $40.42 per share (Code S) via a mandatory “sell-to-cover� transaction to satisfy tax-withholding requirements. After these transactions, Farrow directly owns 36,704 common shares and continues to hold 55,763 unvested/undelivered RSUs granted under the 2020 Stock Plan. The reported sale was non-discretionary and does not indicate a change in the insider’s investment outlook. No other derivative activity, option exercises, or discretionary open-market sales were disclosed.
Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) filed an 8-K disclosing the final voting results of its 12 June 2025 Annual Meeting of Stockholders. Holders of 34.85 million shares (83% of outstanding) constituted a quorum and approved all four proposals.
- Board elections: Dr. Bobak Azamian received 20.8 m “for� votes (75.4%) and 6.8 m withheld; Dr. Katherine Goodrich received 26.8 m “for� votes (97.4%). Both will serve until 2028.
- Say-on-pay: Executive compensation was approved with 27.1 m votes in favor (98.4%).
- Say-on-pay frequency: Shareholders favored an annual vote (26.9 m votes; 97.6%).
- Auditor: Ernst & Young LLP was ratified with 34.7 m votes in favor (99.6%) for FY 2025.
The results signal broad shareholder support for management and governance practices, though the CEO’s support level was materially lower than that of the other elected director.
FAQ
What is the current stock price of Tarsus Pharmaceuticals (TARS)?
What is the market cap of Tarsus Pharmaceuticals (TARS)?
What is the primary focus of Tarsus Pharmaceuticals, Inc.?
What indicates the company’s expertise in eye care?
How does Tarsus generate revenue?
What diseases are targeted by Tarsus' pipeline?
How does Tarsus differentiate itself in the biopharmaceutical market?
What role does clinical research play at Tarsus Pharmaceuticals?
How are new therapies introduced by Tarsus received by the market?
What are some of the key challenges Tarsus faces in its market?
